~
This is very good news for medical marijuan, according to a policy statement released Monday.
 
"The AAP strongly supports research and development of pharmaceutical cannabinoids and supports a review of policies promoting research on the medical use of these compounds," the AAP statement reads. To that end, the group recommends that the DEA reschedule marijuana from a Schedule I controlled substance to Schedule II.
 
Under the Controlled Substances Act, the U.S. has five "schedules" for drugs and chemicals that can be used to make drugs. Schedule I is reserved for drugs that the DEA considers to have the highest potential for abuse and no "currently accepted medical use." Marijuana has been classified as Schedule I for decades, along with other substances like heroin and LSD. While a lower schedule for marijuana would not make it legal, it could ease restrictions on researching the drug.
 
While the AAP added that it does not support the legalization of marijuana, citing the potential harms to children and adolescents, it did say that it "strongly" supports the decriminalization of marijuana use and encourages pediatricians to "advocate for laws that prevent harsh criminal penalties for possession or use of marijuana."
 
"A focus on treatment for adolescents with marijuana use problems should be encouraged, and adolescents with marijuana use problems should be referred to treatment," the statement said.
 
Monday's statement is the first change to AAP policy on the issue since 2004. At that time, the group did not request a schedule change.
 
The DEA is the federal agency that is primarily responsible for regulating controlled substances like marijuana. But the Food and Drug Administration, along with the National Institute on Drug Abuse, provides the DEA with recommendations about the appropriate level of restriction for various illicit substances.
 
The FDA is already engaged in a review of the medical evidence surrounding the safety and effectiveness of marijuana. The evaluation was initiated due to a request from the DEA, following a number of citizens' petitions asking for a review. According to the Controlled Substances Act, the government must consider eight factors when deciding the schedule under which a substance should be classified. These include its potential for abuse, the state of current scientific knowledge about the substance and its psychic or physiological dependence liability.
 
The FDA could not confirm to The Huffington Post how long the review process takes, but expressed support for AAP's move.
 
"FDA can’t comment on the suggestion to change the schedule for marijuana, as the latest FDA review of the issue -- known as the 8-factor analysis -- is currently ongoing, FDA press officer Jeff Ventura said Monday. "However, FDA agrees with the call by the AAP for rigorous scientific research into the uses of marijuana ... [and] supports those in the medical research community who seek to study marijuana."
 
The DEA has made previous requests, in 2001 and 2006, to the FDA for an evaluation of marijuana. Those requests were the results of public petitions requesting a rescheduling, FDA Deputy Director Doug Throckmorton explained in testimony delivered during a congressional hearing last year. But DEA regulators determined after both of those reviews that marijuana should remain a Schedule I substance. The FDA cited insufficient available research about marijuana's effectiveness in treating a number of ailments.
 
While the FDA hasn't advocated for legalization of the drug, it said in a 2014 update to its guidelines on marijuana that it is "aware that there is considerable interest in its use to attempt to treat a number of medical conditions, including, for example, glaucoma, AIDS wasting syndrome, neuropathic pain, cancer, multiple sclerosis, chemotherapy-induced nausea, and certain seizure disorders."
 
Matt Ferner ~ January 27, 2015
 
 
October 17, 2019

The Science Behind Marijuana And Migraines -…

It’s estimated that over 1 billion individuals worldwide suffer from the debilitating pain of migraines. And now new research shows…
October 17, 2019

Ganja Gourmet: Chronic Cheesecake - Cannabis News

It’s creamy and decadent, with a hint of fresh lemon and real vanilla, and the only difficult part of this…
October 17, 2019

Average medical marijuana user in Ohio is…

More than two thirds of Ohio’s medical marijuana cardholders are older than 40.
October 17, 2019

MJ Micro conference brings together public and…

MJ Link, a Subsidiary of Social Like Network (OTCQB: WDLF) CEO Kenn Tapp and President of MJ Micro Todd Markey…
October 17, 2019

Frustration and pride in Canada after a…

The weed is expensive, the selection is limited, the black market persists, and licensed stores are scarce. It’s one year…
October 16, 2019

Semper Fidelis: Twenty22Many Hooks Vets Up With…

Washington-based cannabis advocacy group Twenty22Many is doing its part to provide medical marijuana to military veterans suffering from PTSD.
October 16, 2019

Farmers rejoice: Harvest season flips to seller’s…

If you see a good deal on cannabis in stores this fall, pounce on it. In 2019, the typical harvest…
October 16, 2019

Pennsylvania Senators Move to Legalize Recreational Marijuana…

Two Pennsylvania state senators introduced Senate Bill 350 in Harrisburg on Tuesday which would allow adults 21 and older to…
October 16, 2019

Soldiers are smoking a whole lot more…

Soldiers are smoking a whole lot more weed if they happen to be stationed in or near a state where…
October 15, 2019

Thailand to Host World Ganja Festival 2020…

The event organizers say the World Ganja Festival 2020 will create new opportunities and provide a better understanding of cannabis…
October 15, 2019

Former FDA Chief Wants Federal Government To…

Former Food and Drug Administration (FDA) Commissioner Scott Gottlieb said on Monday that the federal government should regulate state marijuana…